TICKERNERD
Menu
RYTMRYTMHealthcare · Biotechnology

RYTM Stock Forecast: Rhythm Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$93
−0.62% on the day

The 18 Wall Street analysts covering Rhythm Pharmaceuticals, Inc. hold a median 12-month price target of $143 — +54.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 3 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$6.4B
Ticker Nerd rank
85 / 100
Median analyst target
$143
Analysts covering
18
Revenue$71.3M+46.9% y/y
Operating income−$48.6M
Net income−$49.3M
Free cash flow−$9.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.9%
1M
−11.9%
YTD
−13.3%
1Y
−4.5%
From 52W high
−21.1%
From 52W low
+22.4%
$76
$118
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RYTM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rhythm Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
85 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
86
Quality
81
Revisions
81
Issuance
78
Momentum
65
Volatility
64
Accruals
55
Growth
47
Size
20

Value (86): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (47): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (20): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RYTM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RYTM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$100$120$140$160Jan 26Apr 26Jul 26Oct 26RYTMHigh $160Median $143Low $105

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
16 Buy2 Hold0 Sell
Low $105Median $143High $160

The green dot is the last close — the median target sits +54.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Sept 2026Leerink PartnersAssumesOutperform$133
28 Aug 2026Deutsche BankInitiatesHold—
28 Aug 2026Deutsche BankInitiatesHold$120
7 Aug 2026JP MorganMaintainsOverweight$145 → $146
7 Aug 2026JP MorganMaintainsOverweight—
5 Aug 2026CitigroupMaintainsBuy$142 → $143
5 Aug 2026CitigroupMaintainsBuy—
5 Aug 2026CitizensMaintainsMarket Outperform—
5 Aug 2026CitizensMaintainsMarket Outperform$155 → $160
5 Aug 2026RBC CapitalMaintainsOutperform—
5 Aug 2026RBC CapitalMaintainsOutperform$141 → $155
27 July 2026JP MorganInitiatesOverweight$145
27 July 2026JP MorganInitiatesOverweight—
7 July 2026RBC CapitalMaintainsOutperform—
7 July 2026RBC CapitalMaintainsOutperform$137 → $141
16 June 2026Canaccord GenuityMaintainsBuy—
15 June 2026Wells FargoMaintainsOverweight—
7 May 2026Canaccord GenuityMaintainsBuy—
6 May 2026RBC CapitalMaintainsOutperform—
6 May 2026Wells FargoMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RYTM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RYTM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Rhythm Pharmaceuticals, Inc. returned −4.5% against +16.2% for the S&P 500, dividends included.

RYTM vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26RYTMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RYTM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
2
Fundamentals

Rhythm Pharmaceuticals, Inc. (RYTM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−29.9×

Cheaper than 97% of US stocks

Price / sales
26.5×

Cheaper than 8% of US stocks

Price / book
62.1×

Cheaper than 2% of US stocks

EV / EBITDA
−31.5×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
46.9%

Higher than 85% of US stocks

Earnings growth (YoY)
46.9%

Higher than 73% of US stocks

Gross margin
87.5%

Higher than 95% of US stocks

Operating margin
−68.1%

Higher than 15% of US stocks

Net margin
−85.6%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−117.0%

Higher than 12% of US stocks

Return on assets
−31.0%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rhythm Pharmaceuticals, Inc. (RYTM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rhythm Pharmaceuticals, Inc. has a market value of $6.4B and an enterprise value of $6.3B.

  • Revenue in the twelve months to 30 June 2026: $239.9M. The latest quarter grew 46.9% year on year.

  • Net income over the same four quarters: −$205.3M, a −85.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.11.

  • Free cash flow in the twelve months to 30 June 2026: −$106.3M.

  • Shares outstanding: 68.8M.

  • Trailing P/E: −29.9×; forward P/E: −151.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Rhythm Pharmaceuticals, Inc. employs 414 people — $580K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

RYTM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RYTMRhythm Pharmaceuticals, Inc.$6.4B
85
IOVAIovance Biotherapeutics, Inc.$6.3B
91
IMVTImmunovant, Inc.$6.8B
39
LGNDLigand Pharmaceuticals, Inc.$6.0B
70
CGONCG Oncology, Inc.$5.9B
17
SRRKScholar Rock Holding Corp.$5.7B
35
KODKodiak Sciences, Inc.$5.7B
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rhythm Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RYTM news & analysis

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

GlobeNewsWire · 22 Sept 2026positive

Rhythm Pharmaceuticals announced that Health Canada has approved IMCIVREE (setmelanotide) for the additional indication of weight management in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity (HO).

Why it matters — This regulatory approval expands the potential market for Rhythm Pharmaceuticals' IMCIVREE into a new indication and geography, broadening its commercial opportunity for RYTM watchers.

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

Rhythm Pharmaceuticals presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The company participated in the conference as part of its investor outreach.

Why it matters — The presentation gives RYTM watchers direct insight into the company's current business update and management commentary delivered at a major healthcare investment conference.

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

GlobeNewsWire · 10 Sept 2026positive

Rhythm Pharmaceuticals and collaborators will present three posters and three oral presentations at the 64th Annual European Society for Paediatric Endocrinology Meeting in Marseille, France. The presentations include real-world data showing BMI reductions with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity in France, plus Phase 3 analyses demonstrating improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO.

Why it matters — The new clinical data presentations highlight encouraging real-world and Phase 3 results for setmelanotide in acquired hypothalamic obesity, reinforcing the drug's potential in an additional rare disease indication for Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

GlobeNewsWire · 24 Aug 2026positive

Rhythm Pharmaceuticals announced that Japan's MHLW approved IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity. Approximately 5,000 to 8,000 patients are estimated to be living with acquired HO in Japan, and a commercial launch is expected by the end of 2026 pending final pricing determination.

Why it matters — A regulatory approval in Japan expands the potential market for IMCIVREE beyond its existing indications and adds a new country where Rhythm could commercialise the product.

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

The Motley Fool · 23 Aug 2026positive

The article highlights that Rhythm Pharmaceuticals develops medicines for rare forms of obesity that larger drugmakers Eli Lilly and Novo Nordisk cannot treat. It notes that the company has little competition in this target market and mentions that billionaire investor Stanley Druckenmiller is betting on the company.

Why it matters — RYTM watchers would care because the piece points to the company's niche focus on rare obesity with limited competition and notable investor interest.

FAQ

Frequently asked questions about RYTM stock

What is the RYTM stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Rhythm Pharmaceuticals, Inc. have a median 12-month price target of $143, with estimates ranging from $105 to $160. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RYTM stock a buy right now?

Of the 18 analysts covering Rhythm Pharmaceuticals, Inc., 16 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rhythm Pharmaceuticals, Inc. 85 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RYTM?

As at 3 Oct 2026, Rhythm Pharmaceuticals, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (86 of 100).

Will RYTM stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +54.0% from the last close, and Ticker Nerd's factor model ranks Rhythm Pharmaceuticals, Inc. 85 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RYTM stock forecast for 2030?

No analyst covering Rhythm Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RYTM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $105 to $160 over the next 12 months.

How has RYTM stock performed over the past year?

Rhythm Pharmaceuticals, Inc. returned -4.5% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rhythm Pharmaceuticals, Inc. do?

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases.

What is the latest news on RYTM?

The most recent item we track (GlobeNewsWire, 22 Sept 2026): "Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity". Rhythm Pharmaceuticals announced that Health Canada has approved IMCIVREE (setmelanotide) for the additional indication of weight management in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity (HO).

Company

About Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases. The company’s lead product, IMCIVREE (setmelanotide), is a precision medicine used to treat severe obesity and hyperphagia associated with specific melanocortin-4 receptor pathway disorders and acquired hypothalamic obesity. Rhythm Pharmaceuticals serves patients with serious rare conditions that are often underserved by conventional obesity treatments, and its work centers on targeted treatments designed for defined genetic and clinical populations. Based in Boston, Massachusetts, and founded in 2008, the company operates within specialty medicine, where it addresses unmet needs in rare metabolic and endocrine diseases through approved therapies and ongoing clinical development.

CEO Dr. David P. Meeker M.D. · 414 employees · United States · https://rhythmtx.com